SCHEMBL3418657

SCHEMBL3418657

CC(=O)C(=O)NC(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.53
CES1 P23141 1/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
TRPV1 Q8NER1 2/20 0.51
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
MTOR P42345 2/20 0.49
PTGS1 P23219 2/20 0.47
SRD5A2 P31213 1/20 0.47
RORC P51449 1/20 0.46
PTPN1 P18031 2/20 0.46
GSK3B P49841 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20100408 0.86 NPC1 (0.50) CES2CES1NPC1RAB9ACRHBP
SCHEMBL26163219 0.85 CES2 (0.57) CES2CES1NPC1RAB9ACRHBP
SCHEMBL3655196 0.80 CES2 (0.61) CES2CES1NPC1RAB9ACRHBP
SCHEMBL6991977 0.79 CES2 (0.59) CES2CES1NPC1RAB9ACRHBP
SCHEMBL25142228 0.77 CES2 (0.57) CES2CES1NPC1RAB9ACRHBP
SCHEMBL15328058 0.77 PTGS1 (0.59) CES2CES1NPC1RAB9ACRHBP
SCHEMBL1435351 0.76 CES2 (0.75) CES2CES1TRPV1NR4A1NR4A2
SCHEMBL72091 0.76 CES2 (0.67) CES2CES1TRPV1NR4A1NR4A2
SCHEMBL5428269 0.76 HDAC6 (0.56) CES2CES1NPC1RAB9ACRHBP
SCHEMBL3415035 0.76 EPHX2 (0.66) NPC1RAB9ATRPV1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216749-A1 Combination Therapy for Neuroprotection S.H. PHARMA., LTD (KR) 2010-08-26 US claimed
WO-2009045083-A2 COMBINATION THERAPY FOR NEUROPROTECTION S.H. PHARMA., LTD (KR) 2009-04-09 WO claimed
US-20100216749-A1 Combination Therapy for Neuroprotection S.H. PHARMA., LTD (KR) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216749-A1 Combination Therapy for Neuroprotection MPO, BDNF, NLN CES2 2721/4885CES1 3625/4885NPC1 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.